$PODD
INSULET CORP Stock $podd

$podd Overview Financials Valuation SEC Filings Company Website

2018 Q1 Form 10-Q Financial Statement

#000114519718000008 Filed on May 04, 2018

Income Statement

Concept	2018 Q1	2017 Q4	2017 Q1
Revenue	$123.6M	$130.5M	$101.7M
YoY Change	21.5%	26.02%	25.24%
Cost Of Revenue	$47.76M	$51.00M	$42.32M
YoY Change	12.87%	19.72%	13.87%
Gross Profit	$75.80M	$79.51M	$59.40M
YoY Change	27.61%	30.48%	34.84%
Gross Profit Margin	61.34%	60.91%	58.4%
Selling, General & Admin	$55.55M	$61.50M	$47.21M
YoY Change	17.67%	25.51%	21.79%
% of Gross Profit	73.28%	77.35%	79.47%
Research & Development	$20.27M	$18.80M	$17.50M
YoY Change	15.81%	17.5%	34.73%
% of Gross Profit	26.74%	23.65%	29.46%
Depreciation & Amortization	$3.522M	$3.320M	$3.323M
YoY Change	5.99%	-1.19%	-2.89%
% of Gross Profit	4.65%	4.18%	5.59%
Operating Expenses	$75.82M	$80.30M	$64.71M
YoY Change	17.17%	23.35%	25.04%
Operating Profit	$0.00	-$768.0K	-$5.308M
YoY Change	-100.0%	-81.43%	-31.06%
Interest Expense	-$6.200M	-$5.500M	-$4.600M
YoY Change	34.78%	-15.38%	58.62%
% of Operating Profit
Other Income/Expense, Net	-$6.236M		-$4.573M
YoY Change	36.37%		56.29%
Pretax Income	-$6.236M	-$6.900M	-$9.881M
YoY Change	-36.89%	-23.33%	-7.0%
Income Tax	$300.0K	-$400.0K	$96.00K
% Of Pretax Income
Net Earnings	-$6.600M	-$6.860M	-$9.977M
YoY Change	-33.85%	-24.77%	-20.06%
Net Earnings / Revenue	-5.34%	-5.26%	-9.81%
Basic Earnings Per Share	-$0.11
Diluted Earnings Per Share	-$0.11	-$118.6K	-$173.3K
COMMON SHARES
Basic Shares Outstanding	58.48M shares	58.19M shares	57.65M shares
Diluted Shares Outstanding	58.48M shares

Balance Sheet

Concept	2018 Q1	2017 Q4	2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$352.0M	$440.1M	$254.0M
YoY Change	38.58%	47.39%	127.6%
Cash & Equivalents	$203.1M	$272.6M	$76.04M
Short-Term Investments	$148.9M	$167.5M	$178.0M
Other Short-Term Assets	$17.40M	$9.900M	$8.200M
YoY Change	112.2%	39.44%	43.86%
Inventory	$33.04M	$33.79M	$34.33M
Prepaid Expenses	$10.60M	$9.949M
Receivables	$50.38M	$53.37M	$40.65M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$547.1M	$537.2M	$337.2M
YoY Change	62.26%	45.2%	96.2%
LONG-TERM ASSETS
Property, Plant & Equipment	$153.0M	$107.9M	$65.28M
YoY Change	134.42%	141.02%	56.56%
Goodwill	$39.77M	$39.80M	$39.70M
YoY Change	0.19%	0.31%	-0.16%
Intangibles		$4.351M
YoY Change
Long-Term Investments	$164.1M	$125.5M
YoY Change
Other Assets	$15.30M	$1.969M	$605.0K
YoY Change	2428.1%	811.57%	2.89%
Total Long-Term Assets	$292.9M	$279.6M	$107.8M
YoY Change	171.73%	222.51%	29.98%
TOTAL ASSETS
Total Short-Term Assets	$547.1M	$537.2M	$337.2M
Total Long-Term Assets	$292.9M	$279.6M	$107.8M
Total Assets	$840.0M	$816.7M	$445.0M
YoY Change	88.78%	78.86%	74.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$33.85M	$24.41M	$6.413M
YoY Change	427.77%	85.51%	-52.43%
Accrued Expenses	$45.76M	$59.26M	$31.84M
YoY Change	43.72%	43.73%	4.79%
Deferred Revenue	$4.981M	$2.356M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$3.451M	$0.00
YoY Change		-100.0%
Total Short-Term Liabilities	$88.65M	$86.03M	$39.38M
YoY Change	125.12%	54.45%	-20.89%
LONG-TERM LIABILITIES
Long-Term Debt	$569.9M	$566.2M	$336.8M
YoY Change	69.22%	70.14%	93.9%
Other Long-Term Liabilities	$6.301M	$6.030M	$5.231M
YoY Change	20.45%	19.83%	6.28%
Total Long-Term Liabilities	$576.2M	$572.2M	$342.0M
YoY Change	68.48%	69.39%	91.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$88.65M	$86.03M	$39.38M
Total Long-Term Liabilities	$576.2M	$572.2M	$342.0M
Total Liabilities	$661.1M	$658.2M	$381.4M
YoY Change	73.35%	67.28%	66.99%
SHAREHOLDERS EQUITY
Retained Earnings	-$686.9M	-$707.3M	-$690.4M
YoY Change	-0.51%	3.94%	3.97%
Common Stock	$59.00K	$58.00K	$58.00K
YoY Change	1.72%	1.75%	1.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$170.6M	$158.5M	$63.59M
YoY Change
Total Liabilities & Shareholders Equity	$840.0M	$816.7M	$445.0M
YoY Change	88.78%	78.86%	74.65%

Cashflow Statement

Concept	2018 Q1	2017 Q4	2017 Q1
OPERATING ACTIVITIES
Net Income	-$6.600M	-$6.860M	-$9.977M
YoY Change	-33.85%	-24.77%	-20.06%
Depreciation, Depletion And Amortization	$3.522M	$3.320M	$3.323M
YoY Change	5.99%	-1.19%	-2.89%
Cash From Operating Activities	-$4.266M	$21.80M	-$21.84M
YoY Change	-80.46%	8.62%	107.62%
INVESTING ACTIVITIES
Capital Expenditures	$35.37M	-$29.42M	$25.68M
YoY Change	37.75%	911.0%	712.63%
Acquisitions
YoY Change
Other Investing Activities	-$20.61M	-$119.9M	-$16.61M
YoY Change	24.08%	27.17%	-460.3%
Cash From Investing Activities	-$55.99M	-$149.3M	-$42.29M
YoY Change	32.4%	53.64%	-3008.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	-$2.261M		$6.335M
YoY Change	-135.69%		695.85%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$8.870M	297.9M	$2.927M
YoY Change	-403.04%	-30190.91%	-234.02%
NET CHANGE
Cash From Operating Activities	-$4.266M	21.80M	-$21.84M
Cash From Investing Activities	-$55.99M	-149.3M	-$42.29M
Cash From Financing Activities	-$8.870M	297.9M	$2.927M
Net Change In Cash	-$69.12M	170.4M	-$61.19M
YoY Change	12.96%	-318.17%	444.09%
FREE CASH FLOW
Cash From Operating Activities	-$4.266M	$21.80M	-$21.84M
Capital Expenditures	$35.37M	-$29.42M	$25.68M
Free Cash Flow	-$39.64M	$51.22M	-$47.51M
YoY Change	-16.57%	122.89%	247.4%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001145197
CY2018Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	58744475	shares
CY2018Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2018Q1	dei	Entity Registrant Name EntityRegistrantName	INSULET CORPORATION
CY2018Q1	podd	Capitalized Contract Cost Noncurrent CapitalizedContractCostNoncurrent	14400000	USD
CY2018Q1	dei	Amendment Flag AmendmentFlag	false
CY2018Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2018Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018Q1	dei	Document Period End Date DocumentPeriodEndDate	2018-03-31
CY2018Q1	dei	Document Type DocumentType	10-Q
CY2018Q1	dei	Trading Symbol TradingSymbol	PODD
CY2017Q4	podd	Accrued Freight Current AccruedFreightCurrent	1148000	USD
CY2018Q1	podd	Accrued Freight Current AccruedFreightCurrent	795000	USD
CY2018Q1	podd	Capitalized Contract Cost Current CapitalizedContractCostCurrent	6900000	USD
CY2017Q4	podd	Capitalized Contract Cost Net Current CapitalizedContractCostNetCurrent	0	USD
CY2018Q1	podd	Capitalized Contract Cost Net Current CapitalizedContractCostNetCurrent	6851000	USD
CY2017Q4	podd	Capitalized Contract Cost Net Noncurrent CapitalizedContractCostNetNoncurrent	0	USD
CY2018Q1	podd	Capitalized Contract Cost Net Noncurrent CapitalizedContractCostNetNoncurrent	14442000	USD
CY2017Q1	podd	Debt Instrument Stated Coupon Rate Interest Expense DebtInstrumentStatedCouponRateInterestExpense	1413000	USD
CY2018Q1	podd	Debt Instrument Stated Coupon Rate Interest Expense DebtInstrumentStatedCouponRateInterestExpense	2480000	USD
CY2018Q1	podd	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	150	Security
CY2018Q1	podd	Finite Lived Intangible Assets Amortization Expense Thereafter FiniteLivedIntangibleAssetsAmortizationExpenseThereafter	36000	USD
CY2018Q1	podd	Finited Lived Intangible Assets Excluding Software In Process Of Development Net FinitedLivedIntangibleAssetsExcludingSoftwareInProcessOfDevelopmentNet	4570000	USD
CY2017Q1	podd	Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities	-14226000	USD
CY2018Q1	podd	Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities	-20950000	USD
CY2017Q1	podd	Increase Decrease In Accounts Receivable And Unbilled Revenue IncreaseDecreaseInAccountsReceivableAndUnbilledRevenue	12146000	USD
CY2018Q1	podd	Increase Decrease In Accounts Receivable And Unbilled Revenue IncreaseDecreaseInAccountsReceivableAndUnbilledRevenue	-1800000	USD
CY2017Q1	podd	Interestand Other Expense Total InterestandOtherExpenseTotal	5407000	USD
CY2018Q1	podd	Interestand Other Expense Total InterestandOtherExpenseTotal	9643000	USD
CY2018Q1	podd	Number Of Financial Institution NumberOfFinancialInstitution	1	location
CY2017	podd	Percentage Of Accounts Payable Accrued Expensesand Other Current Liabilities PercentageOfAccountsPayableAccruedExpensesandOtherCurrentLiabilities	0.20
CY2018Q1	podd	Percentage Of Accounts Payable Accrued Expensesand Other Current Liabilities PercentageOfAccountsPayableAccruedExpensesandOtherCurrentLiabilities	0.13
CY2017	podd	Tax Cuts And Jobs Act Of2017 Transition Tax For Accumulated Foreign Earnings Tax Expense Increase Decrease In Valuation Allowance TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsTaxExpenseIncreaseDecreaseInValuationAllowance	-800000	USD
CY2017Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	59256000	USD
CY2018Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	45759000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	24413000	USD
CY2018Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	33846000	USD
CY2017Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3542000	USD
CY2018Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	2136000	USD
CY2017	podd	Tax Cuts And Jobs Act Of2017 Transition Tax For Accumulated Foreign Earnings Tax Expense Reduction In Net Operating Loss TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsTaxExpenseReductionInNetOperatingLoss	-800000	USD
CY2017Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	55914000	USD
CY2018Q1	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	53214000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	53373000	USD
CY2018Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	50383000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	59256000	USD
CY2018Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	45759000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	9273000	USD
CY2018Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	8920000	USD
CY2017Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	34942000	USD
CY2018Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	20253000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	51600000	USD
CY2018Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	54700000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-493000	USD
CY2018Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1536000	USD
CY2018Q1	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P3Y7M1D
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	866206000	USD
CY2018Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	865520000	USD
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7124000	USD
CY2018Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8180000	USD
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2541000	USD
CY2018Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2831000	USD
CY2017Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	3504000	USD
CY2018Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	6522000	USD
CY2017Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	490000	USD
CY2018Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	641000	USD
CY2017Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	3994000	USD
CY2018Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	7163000	USD
CY2017Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	300000	USD
CY2018Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	400000	USD
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11948332	shares
CY2018Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14712884	shares
CY2017Q4	us-gaap	Assets Assets	816744000	USD
CY2018Q1	us-gaap	Assets Assets	829763000	USD
CY2018Q1	us-gaap	Assets Assets	840004000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	537171000	USD
CY2018Q1	us-gaap	Assets Current AssetsCurrent	451611000	USD
CY2018Q1	us-gaap	Assets Current AssetsCurrent	547105000	USD
CY2017Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	167479000	USD
CY2018Q1	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	148853000	USD
CY2018Q1	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0	USD
CY2017	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	17500000	USD
CY2018Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	4000000	USD
CY2018Q1	us-gaap	Capitalized Contract Cost Accumulated Amortization CapitalizedContractCostAccumulatedAmortization	1600000	USD
CY2018Q1	us-gaap	Capitalized Contract Cost Accumulated Impairment CapitalizedContractCostAccumulatedImpairment	0	USD
CY2018Q1	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	21300000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	137174000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	76038000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	272577000	USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	58319348	shares
CY2018Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	58723242	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	58319348	shares
CY2018Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	58723242	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	58000	USD
CY2018Q1	us-gaap	Common Stock Value CommonStockValue	59000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9908000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	203146000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-61136000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-69431000	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7612000	USD
CY2018Q1	us-gaap	Contract With Customer Asset Reclassified To Receivable ContractWithCustomerAssetReclassifiedToReceivable	5100000	USD
CY2018Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	2100000	USD
CY2018Q1	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	0	USD
CY2017Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	42315000	USD
CY2018Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	47763000	USD
CY2017Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	170448000	USD
CY2018Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	163925000	USD
CY2017Q4	us-gaap	Deferred Costs And Other Assets DeferredCostsAndOtherAssets	1969000	USD
CY2018Q1	us-gaap	Deferred Costs And Other Assets DeferredCostsAndOtherAssets	16663000	USD
CY2017Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	14543000	USD
CY2018Q1	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	13902000	USD
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2356000	USD
CY2018Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2809000	USD
CY2018Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	4981000	USD
CY2017Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3323000	USD
CY2018Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3522000	USD
CY2017Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	58000	USD
CY2018Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-307000	USD
CY2018Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	59512000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	5329000	USD
CY2018Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	5682000	USD
CY2018Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1299000	USD
CY2018Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	1158000	USD
CY2018Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	425000	USD
CY2018Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	683000	USD
CY2018Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	969000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	9680000	USD
CY2018Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	10252000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	4351000	USD
CY2018Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	4570000	USD
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	19111000	USD
CY2018Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	23770000	USD
CY2017Q4	us-gaap	Goodwill Goodwill	39840000	USD
CY2018Q1	us-gaap	Goodwill Goodwill	39773000	USD
CY2018Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2017Q1	us-gaap	Gross Profit GrossProfit	59398000	USD
CY2018Q1	us-gaap	Gross Profit GrossProfit	75815000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-9881000	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-6236000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.17
CY2018Q1	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.11
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	96000	USD
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	300000	USD
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	333000	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-87000	USD
CY2018Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-2165000	USD
CY2017Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1175000	USD
CY2018Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-6706000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	111000	USD
CY2018Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	627000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1421000	USD
CY2018Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3324000	USD
CY2017Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	5007000	USD
CY2018Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	7918000	USD
CY2017Q4	us-gaap	Interest Payable Current InterestPayableCurrent	2030000	USD
CY2018Q1	us-gaap	Interest Payable Current InterestPayableCurrent	2353000	USD
CY2017Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	7729000	USD
CY2018Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	11483000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	33793000	USD
CY2018Q1	us-gaap	Inventory Net InventoryNet	26334000	USD
CY2018Q1	us-gaap	Inventory Net InventoryNet	33040000	USD
CY2017Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2146000	USD
CY2018Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	3173000	USD
CY2017Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	23918000	USD
CY2018Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	11678000	USD
CY2017Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	600000	USD
CY2018Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	800000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	658228000	USD
CY2018Q1	us-gaap	Liabilities Liabilities	659195000	USD
CY2018Q1	us-gaap	Liabilities Liabilities	661124000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	816744000	USD
CY2018Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	829763000	USD
CY2018Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	840004000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	86025000	USD
CY2018Q1	us-gaap	Liabilities Current LiabilitiesCurrent	82414000	USD
CY2018Q1	us-gaap	Liabilities Current LiabilitiesCurrent	88650000	USD
CY2017Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2018Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	3451000	USD
CY2017Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	566173000	USD
CY2018Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	569877000	USD
CY2017Q4	us-gaap	Long Term Investments LongTermInvestments	125549000	USD
CY2018Q1	us-gaap	Long Term Investments LongTermInvestments	164117000	USD
CY2015Q2	us-gaap	Loss Contingency Claims Dismissed Number LossContingencyClaimsDismissedNumber	2	LegalMatter
CY2015Q2	us-gaap	Loss Contingency New Claims Filed Number LossContingencyNewClaimsFiledNumber	3	LegalMatter
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2927000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-8870000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-42286000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-55988000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21835000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4266000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-9977000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-6569000	USD
CY2017Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4573000	USD
CY2018Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6236000	USD
CY2018Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	64706000	USD
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	75815000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5308000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	0	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	12517000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	2986000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due In Rolling Year Four OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour	2131000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due In Rolling Year Three OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree	2383000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due In Rolling Year Two OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo	2619000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	0	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	2398000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	6668000	USD
CY2018Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5923000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1969000	USD
CY2018Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2221000	USD
CY2018Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	15295000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	79000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-318000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	69000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1043000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-10000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-725000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6030000	USD
CY2018Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6904000	USD
CY2018Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6301000	USD
CY2017Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	434000	USD
CY2018Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1682000	USD
CY2017Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	0	USD
CY2018Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	46000	USD
CY2018Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	700000	USD
CY2017Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	3139000	USD
CY2018Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	11816000	USD
CY2017Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	41347000	USD
CY2018Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	60880000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	25679000	USD
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	35374000	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2018Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9949000	USD
CY2018Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	17449000	USD
CY2018Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	15517000	USD
CY2017Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	9949000	USD
CY2018Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	10598000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6335000	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2961000	USD
CY2017Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	24740000	USD
CY2018Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	40266000	USD
CY2016Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	4388000	USD
CY2017Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	4562000	USD
CY2017Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	5337000	USD
CY2018Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	5386000	USD
CY2017Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	1653000	USD
CY2018Q1	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	1928000	USD
CY2017Q4	us-gaap	Product Warranty Accrual Noncurrent ProductWarrantyAccrualNoncurrent	3684000	USD
CY2018Q1	us-gaap	Product Warranty Accrual Noncurrent ProductWarrantyAccrualNoncurrent	3458000	USD
CY2017Q1	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	1289000	USD
CY2018Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	697000	USD
CY2018Q1	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	1923000	USD
CY2017Q1	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	1463000	USD
CY2018Q1	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	1972000	USD
CY2017Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
CY2018Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	15000	USD
CY2017Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	269000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	107864000	USD
CY2018Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	153029000	USD
CY2017Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	295000	USD
CY2018Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	0	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17500000	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19912000	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	500000	USD
CY2018Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	500000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-707255000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-693475000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-686906000	USD
CY2017Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	101713000	USD
CY2018Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	123578000	USD
CY2017Q1	us-gaap	Sales Revenue Net SalesRevenueNet	101713000	USD
CY2018Q1	us-gaap	Sales Revenue Net SalesRevenueNet	123578000	USD
CY2017Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	28095000	USD
CY2018Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	32133000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7124000	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	8181000	USD
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	4000000	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2042078	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	34.14
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	4900000	USD
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	5438000	USD
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	5400000	USD
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	64757	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	234689	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	167501000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3377220	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3433110	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	35.10
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	37.89
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	161681000	USD
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3280220	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	31.35
CY2018Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	36.18
CY2018Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	74.39
CY2018Q1	us-gaap	Share Price SharePrice	86.68
CY2018Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	107296000	USD
CY2018Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y10M24D
CY2018Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y6M
CY2017Q1	us-gaap	Shipping Handling And Transportation Costs ShippingHandlingAndTransportationCosts	1300000	USD
CY2018Q1	us-gaap	Shipping Handling And Transportation Costs ShippingHandlingAndTransportationCosts	1000000	USD
CY2018Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	114042	shares
CY2018Q1	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	8243	shares
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	158516000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	170568000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	178880000	USD
CY2017Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	0	USD
CY2018Q1	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	5446000	USD
CY2018Q1	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	5119000	USD
CY2018Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	57693930	shares
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	58482786	shares
CY2018Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nature of the Business </font></div><div style="line-height:120%;padding-top:12px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Insulet Corporation (the "Company") is primarily engaged in the development, manufacturing and sale of its proprietary Omnipod Insulin Management System (the “Omnipod System”), an innovative, discreet and easy-to-use continuous insulin delivery system for people with insulin-dependent diabetes. There are two</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font><font style="font-family:inherit;font-size:10pt;">primary types of insulin therapy practiced today: multiple daily injection (“MDI”) therapy using syringes or insulin pens; and pump therapy using insulin pumps. Insulin pumps are used to perform continuous subcutaneous insulin infusion, or insulin pump therapy, and typically use a programmable device and an infusion set to administer insulin into the person’s body. Insulin pump therapy has been shown to provide people with insulin-dependent diabetes with numerous advantages relative to MDI therapy. The Company estimates that approximately one-third of the Type 1 diabetes population in the United States use insulin pump therapy, and that less than 10% of the Type 2 diabetes population in the United States who are insulin-dependent use insulin pump therapy.</font><font style="font-family:inherit;font-size:10pt;color:#ff0000;"> </font><font style="font-family:inherit;font-size:10pt;">The Omnipod System features a small, lightweight, self-adhesive disposable tubeless Omnipod device which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager ("PDM"). The Omnipod System, which features two discreet, easy-to-use devices that communicate wirelessly and provide for virtually pain-free automated cannula insertion and blood glucose meter integration, eliminates the need for traditional MDI therapy or the use of traditional pump and tubing. The Company believes that the Omnipod System’s unique proprietary design and features allow people with insulin-dependent diabetes to manage their diabetes with unprecedented freedom, comfort, convenience, and ease.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial sales of the Omnipod System began in the United States in 2005. The Company sells the Omnipod System in the United States through direct sales to customers or through its distribution partners. The Omnipod System is currently available in multiple countries in Europe, as well as in Canada and Israel. </font></div><div style="line-height:120%;padding-top:12px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To lower manufacturing costs, increase supply redundancy, add capacity closer to its largest customer base and support growth, the Company is constructing a highly-automated manufacturing facility in Acton, Massachusetts, with planned production out of the facility beginning in early 2019. The facility will also serve as the Company's global headquarters.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">The Company announced on July 20, 2017 its plans to assume, on July 1, 2018, all commercial activities (including, among other things, distribution, sales, marketing, training and support) of its Omnipod System across Europe following the expiration of its distribution agreement with Ypsomed Distribution AG ("Ypsomed" or the "European distributor") on June 30, 2018. Until the expiration of the distribution agreement, the Company's current distribution agreement for its Omnipod products in Europe will remain in effect. The Company will be required to pay to the European distributor a per unit fee for sales of the Company's Omnipod device over the subsequent twelve months following the expiration of the distribution agreement. The fee will be based on sales of the Omnipod device to identified customers (as that term is defined in the distribution agreement) of the European distributor who had previously entered into an agreement with the distributor for the purchase of Omnipod devices. The Company expects to recognize a liability for this fee as qualifying sales of its Omnipod device are made to these identified customers during the twelve-month period beginning July 1, 2018. </font></div><div style="line-height:120%;padding-top:12px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to using the Omnipod System for insulin delivery, the Company also partners with global pharmaceutical and biotechnology companies to tailor the Omnipod System technology platform for the delivery of subcutaneous drugs across multiple therapeutic areas.</font></div></div>
CY2018Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates in Preparation of Financial Statements</font></div><div style="line-height:120%;padding-top:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions in the application of certain of its significant accounting policies that may materially affect the reported amounts of assets, liabilities, equity, revenue and expenses. Actual results may differ from those estimates. See Note 3 related to the Company's adoption of ASU No. 2014-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers, </font><font style="font-family:inherit;font-size:10pt;">for a discussion of judgments associated with the recognition of revenue and deferral of cost to obtain a contract. </font></div></div>

Files In Submission

Name	View Source	Status
0001145197-18-000008-index-headers.html	Edgar Link	pending
0001145197-18-000008-index.html	Edgar Link	pending
0001145197-18-000008.txt	Edgar Link	pending
0001145197-18-000008-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
podd-20180331.xml	Edgar Link	completed
podd-20180331.xsd	Edgar Link	pending
podd-20180331_cal.xml	Edgar Link	unprocessable
podd-20180331_def.xml	Edgar Link	unprocessable
podd-20180331_lab.xml	Edgar Link	unprocessable
podd-20180331_pre.xml	Edgar Link	unprocessable
podd-2018x03x31_10q.htm	Edgar Link	pending
podd-exx311_20180331x10q.htm	Edgar Link	pending
podd-exx312_20180331x10q.htm	Edgar Link	pending
podd-exx321_20180331x10q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PODD
INSULET CORP Stock $podd

2018 Q1 Form 10-Q Financial Statement

#000114519718000008 Filed on May 04, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PODD INSULET CORP Stock $podd

2018 Q1 Form 10-Q Financial Statement

#000114519718000008 Filed on May 04, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PODD
INSULET CORP Stock $podd